White House appoints NCI Director Andrew von Eschenbach acting FDA commissioner after Lester Crawford resigns.
Von Eschenbach says he will continue as NCI director and give both jobs “100 percent.”
Members of Congress say that won’t work.
Legal experts say too many conflicts involved. HHS gave von Eschenbach a waiver for his role in C-Change.
After a “humble” start at NCI, von Eschenbach set unachievable goal.
Trending Stories
- DOD cancer research programs face 57% funding cut in year-long continuing resolution
Pancreatic, lung, kidney cancer research programs eliminated - What Trump’s pick of RFK Jr. means for cancer: Epidemics, HPV, stunted research
Former FDA Commissioner Scott Gottlieb expresses “deep concerns” - Kennedy announces massive cuts, centralization at HHS—NCI and FDA hit
Also this week: Columbia yields, Makary and Bhattacharya confirmed, tariffs on pharmaceuticals, and more changes impacting oncology - In The Headlines: HHS shakeup threatens a legacy of medical breakthroughs
- Alec Kimmelman named director of Perlmutter Cancer Center, quickly replacing ousted Benjamin Neel
- Jonathan Friedberg tells us how he built a cancer center in an underserved area of New York State